RxDoctor Payments Data

Matthew Miles, DO

Pulmonary Disease · Charlotte, NCNPI 1588009310

Payments from drug & device makers

$8,162in general payments, 2019–2025

Across 112 payments — averaging $72.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$6K
  • GSK$1K
  • Merck$252
  • Medtronic$162
  • Johnson & Johnson$110
  • Grifols USA, LLC$73
  • plus $363 from 14 others

What the payments were for

  • Travel & lodging$1,13114%
  • Food & beverage$2,98837%
  • Education$4,02849%
  • Gifts$150%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,162 in reported general payments places this provider in the 70th percentile of 393 pulmonary disease providers in North Carolina.

See all pulmonary disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$89,227
Medicare patients
356
Services billed
1,151

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter382$327,106
Prolastin CAlpha-1-Proteinase Inhibitor11$101,624
Fasenra PenBenralizumab16$90,661
TezspireTezepelumab-Ekko19$84,913
Pirfenidone17$55,471
Breztri AerosphereBudesonide/Glycopyr/Formoterol59$44,961
Breo ElliptaFluticasone/Vilanterol53$24,552
Stiolto RespimatTiotropium Br/Olodaterol Hcl22$13,352
Albuterol Sulfate HfaAlbuterol Sulfate152$5,453
SymbicortBudesonide/Formoterol Fumarate21$5,248
Azelastine-FluticasoneAzelastine/Fluticasone28$4,742
Ventolin HfaAlbuterol Sulfate23$1,469
Fluticasone Propionate97$1,300
Ipratropium Bromide24$1,232
Prednisone82$374

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$1,060$351,658435 claims
AstraZenecaTezspire, Breztri Aerosphere, Symbicort$42$135,12399 claims
Grifols USA, LLCProlastin C$73$101,62411 claims
Boehringer IngelheimStiolto Respimat$53$13,35222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 393 pulmonary disease providers in North Carolina.

Other pulmonary disease in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →